Neratinib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
G-BA (Germany), NICE (England) and SMC (Scotland), among others, recommended or restricted neratinib, while AOTMIT (Poland), CIPM (Spain) and DMC (Denmark), among others, did not recommend it.
The record spans 3 years, opening at AWMSG (Wales) on 6 Feb 2019 and running to 3 Feb 2022.
No assessment is on file from HAS (France) and PHARMAC (New Zealand), each among the eight highest-volume agencies here.
Against its own class, neratinib is an outlier: 44% of its decisive outcomes were positive, where molecules sharing ATC class L01E average 75%.
5 distinct indication wordings are recorded for neratinib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 11 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess neratinib, on 6 Feb 2019; CIPM (Spain) did not open a file until 3 Feb 2022 — a wide spread of 3 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 5 of 11 dated records fall in 2020 alone.
PBAC (Australia) is the only agency to have returned to neratinib, recording 2 separate entries.
10 of the 18 agencies in this archive hold a record for neratinib.
The full ledger for neratinib reads 5 not recommended, 4 recommended, 1 deferred to NICE and 1 other.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 3 Feb 2022 | Indicaciones terapéuticas autorizadas: Nerlynx (neratinib) está indicado en adultos para el tratamiento adyuvante extend… | not financed by the SNS · art. 92 c, d | source |
| DMC (Denmark) | 12 Mar 2021 | Brystkræft | Ikke anbefalet | source |
| AOTMIT (Poland) | 7 Sep 2020 | Nerlynx reimbursement recommendation | not recommended | source |
| SMC (Scotland) | 10 Aug 2020 | Extended adjuvant treatment of adult patients with early-Etage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab… | accepted | source |
| NYE METODER (Norway) | 21 Jun 2020 | Forlenget adjuvant behandling av voksne pasienter i tidlig stadium av hormonreseptorpositiv HER2 - overuttrykt/forsterke… | not introduced | source |
6 further decisions for neratinib, across 5 agencies, are not shown here. They link to 5 further source documents.
Related molecules
- letrozole — divergent outcome (not recommended vs recommended) on a shared indication
- ribociclib — divergent outcome (not recommended vs recommended) on a shared indication
- pertuzumab — divergent outcome (not recommended vs recommended) on a shared indication
- pembrolizumab — divergent outcome (not recommended vs recommended) on a shared indication
- trastuzumab emtansine — divergent outcome (not recommended vs recommended) on a shared indication
- ibrutinib — same ATC class L01E — Antineoplastics
Coverage: 11 decisions for neratinib from 10 agencies, 2019 to 2022. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.